Address
320 West 37th Street
New York City, NY 10018
United States of America (the)
Phone
917 580 3099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
362
First IPO Date
June 21, 2019
| Name | Title | Pay | Year Born |
| Eric Venker | Chief Executive Officer & Director | 55,000 | 1987 |
| Frank Torti | Executive Chairperson of the Board | 92,500 | 1979 |
| Christopher Van Tuyl | Chief Legal Officer & Corporate Secretary | 549,038 | 1976 |
| Melanie Gloria | Chief Operating Officer | 575,913 | 1978 |
| Jay S. Stout | Chief Technology Officer | 683,490 | 1964 |
| Tiago Girao | Chief Financial Officer | 871,065 | 1979 |
| Andy Deig | Senior Vice President of Strategic Finance | 0 | N/A |
| Becky Merlina | Senior VP & Global Head of Quality | 0 | N/A |
| Christine Blodgett | Senior Vice President of Human Resources | 0 | N/A |
| Julie Kirschling | Senior Vice President of Program & Alliance Management | 0 | N/A |
| Sheetal Patel | Senior Vice President of Clinical Development | 0 | N/A |
| Yan Zheng | Senior Vice President of Biostatistics, Programming & Data Management | 0 | N/A |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.